BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 11, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Droxidopa: Additional Phase III data

The company previously reported data showing that the trial, which enrolled 101 patients with NOH, missed the primary endpoint of significantly improving dizziness or light-headedness on the OHSA scale vs. placebo, as well as various secondary endpoints (see BioCentury, Sept. 28, 2009 & Oct. 5, 2009). The compound has Fast Track and Orphan Drug designations to treat symptomatic NOH in the U.S. and Orphan designation to...

Read the full 308 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >